ARTICLE | Clinical News
GVAX vaccine for pancreatic cancer: Preliminary Phase II data
November 21, 2005 8:00 AM UTC
Preliminary data from a U.S. Phase II trial in 60 patients showed that GVAX vaccine led to 1-year and 2-year survival rates of 88% and 76%. Historical data published in the July 2005 issue of the Jour...